PET bei hirntumoren

Keyphrases

• Positron Emission Tomography 100%
• Tyrosine 100%
• Sub-volume 100%
• Brain Tumor 100%
• Radiopharmaceuticals 100%
• 11C-methionine 100%
• Tumor 50%
• Normal Brain 50%
• 18F-fluorodeoxyglucose (18F-FDG) 50%
• Tumor Tissue 50%
• High-dose Radiation 50%
• Cancer Cells 50%
• Tumor Hypoxia 50%
• High Glucose 50%
• Glucose Utilization 50%
• Meningioma 50%
• Aggressiveness 50%
• Tumor Proliferation 50%
• Recurrent Tumor 50%
• Glioma 50%
• Gray Matter 50%
• Radiolabeled Amino Acids 50%
• Intensity-modulated Radiotherapy 50%
• Ongoing Clinical Trials 50%
• Glucose Analogues 50%
• 68Gallium 50%
• Extracranial Tumors 50%
• Radiation Treatment Planning 50%
• Somatostatin Analogs 50%
• Poor Contrast 50%
• MRI Brain Tumor 50%

Pharmacology, Toxicology and Pharmaceutical Science

• Intracranial Tumor 100%
• Neoplasm 100%
• Fluorine 18 66%
• Methionine 66%
• Carbon 11 66%
• Clinical Trial 33%
• Malignant Neoplasm 33%
• Amino Acid 33%
• Fluorodeoxyglucose F 18 33%
• Tumor Growth 33%
• Hypoxia 33%
• Tumor Recurrence 33%
• Somatostatin Derivative 33%
• Glucose Derivative 33%
• Meningioma 33%

Neuroscience

• Fluorine-18 100%
• Positron Emission Tomography 100%
• Intracranial Tumor 100%
• Methionine 66%
• Radiopharmaceutical 66%
• Radiation Therapy 66%
• Gray Matter 33%
• Amino Acid 33%
• Somatostatin Derivative 33%
• Glucose Derivative 33%
• Meningioma 33%